Clinical Trial Update: Integrative Analysis of Tumor Microenvironment and Optimization of Immunotherapy Duration in NSCL Cancer Patients [Phase 2]

View source ↗

Summary

Phase 2 trial in Non-Small Cell Lung Cancer investigating tumor microenvironment and optimal duration of immunotherapy has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Snippet

Sponsor: Institut Bergonié | Conditions: Non Small Cell Lung Cancer | Phase 2 | Status: TERMINATED